NHG assists CAF in investment for DIABEVID test development
Nader Hayaux & Goebel has advised Corporación Andina de Fomento (CAF) on an investment in favour of Patia Biopharma, which will be used to develop the “DIABEVID” test, a cost-effective genetic test to identify diabetic patients at high risk of contracting SARS-Cov-2.
The development of this test will allow to detect the high risk of diabetic patients of contracting SARS-Cov-2, in order to take precautionary measures, through testing and sample collection in Spain, Mexico and Peru.
Patia Biopharma was assisted by a team of in-house counsel from Grupo Financiero Inbursa, including lawyers José Francisco Vergara Gómez and Ricardo Anaya Haro.
CAF’s in-house counsel team was represented by Adriana Ospina.
NHG’s team consisted of partner José Humberto Rocha (pictured left) and associate José María Castro (pictured right).
